Amgen Inc. $AMGN Shares Acquired by Global Wealth Management Investment Advisory Inc.

Global Wealth Management Investment Advisory Inc. boosted its position in Amgen Inc. (NASDAQ:AMGN) by 56.2% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 13,056 shares of the medical research company’s stock after purchasing an additional 4,699 shares during the period. Global Wealth Management Investment Advisory Inc.’s holdings in Amgen were worth $3,684,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Legacy Investment Solutions LLC bought a new position in Amgen during the second quarter valued at about $27,000. Evelyn Partners Investment Management LLP acquired a new stake in Amgen in the 2nd quarter valued at about $32,000. Howard Hughes Medical Institute bought a new position in shares of Amgen during the 2nd quarter valued at about $32,000. Quaker Wealth Management LLC boosted its position in shares of Amgen by 200.0% during the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after purchasing an additional 240 shares in the last quarter. Finally, Nvwm LLC grew its stake in shares of Amgen by 893.3% in the 2nd quarter. Nvwm LLC now owns 149 shares of the medical research company’s stock worth $42,000 after purchasing an additional 134 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Insider Activity at Amgen

In other news, EVP Murdo Gordon sold 6,879 shares of the business’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the transaction, the executive vice president directly owned 41,923 shares in the company, valued at $14,120,924.09. The trade was a 14.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the transaction, the senior vice president directly owned 7,082 shares in the company, valued at $2,381,251.68. This trade represents a 11.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 10,908 shares of company stock valued at $3,674,966. Corporate insiders own 0.69% of the company’s stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Multiple sell‑side firms reiterated Buy ratings and bullish outlooks — William Blair kept a Buy, BMO highlighted pipeline momentum, and Goldman Sachs reiterated Buy with a $403 target, all reinforcing upside expectations for AMGN. Amgen: Durable Growth from Core Franchises and High‑Value MariTide Catalysts Support Buy Rating
• Positive Sentiment: Goldman Sachs cites strong portfolio execution and six growth drivers, keeping a high price target that suggests meaningful upside from current levels if execution continues. Amgen Growth Story Isn’t Tapped Out Yet, Says Goldman
• Positive Sentiment: Amgen reported extension and mid‑stage diabetes data for MariTide showing patients maintained weight loss and saw improved glycemic control — data that bolsters MariTide as a high‑value potential obesity/diabetes franchise. Amgen says MariTide helped trial patients maintain weight loss
• Neutral Sentiment: Amgen presented at the J.P. Morgan Healthcare Conference (transcript available) — useful for longer‑term visibility on pipeline and strategy but not an immediate earnings surprise. Amgen Inc. (AMGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
• Neutral Sentiment: Ro (telehealth) launched a research collaboration with Amgen to study barriers to obesity care and GLP‑1 access — this could help real‑world adoption and payer conversations over time but has no immediate revenue impact. Ro partners with Amgen to study barriers to obesity care, GLP-1 access
• Neutral Sentiment: Coverage pieces from Zacks highlight investor attention and potential earnings surprises in the sector — signals that AMGN is on screens but not a direct catalyst. These 2 Medical Stocks Could Beat Earnings
• Negative Sentiment: Despite the MariTide readouts, the stock fell as some investors said the data failed to excite — indicating a gap between expectations and what was disclosed, and suggesting near‑term volatility until larger confirmatory data or clearer commercial signals arrive. Amgen Stock (AMGN) Falls despite Obesity Drug Update — Here’s Wall Street’s Take

Amgen Stock Performance

Shares of Amgen stock opened at $324.30 on Wednesday. The stock has a market cap of $174.63 billion, a PE ratio of 25.06, a price-to-earnings-growth ratio of 2.97 and a beta of 0.45. The business has a fifty day simple moving average of $330.88 and a 200-day simple moving average of $305.32. The company has a quick ratio of 0.99, a current ratio of 1.28 and a debt-to-equity ratio of 5.45. Amgen Inc. has a 12 month low of $261.43 and a 12 month high of $346.38.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating the consensus estimate of $5.01 by $0.63. Amgen had a return on equity of 162.59% and a net margin of 19.47%.The firm had revenue of $9.56 billion for the quarter, compared to analyst estimates of $8.98 billion. During the same period in the previous year, the firm earned $5.58 earnings per share. Amgen’s quarterly revenue was up 12.4% on a year-over-year basis. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a dividend of $2.52 per share. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Friday, February 13th. Amgen’s dividend payout ratio is 73.57%.

Analyst Ratings Changes

Several research firms recently commented on AMGN. Deutsche Bank Aktiengesellschaft increased their target price on shares of Amgen from $280.00 to $285.00 and gave the company a “hold” rating in a research note on Tuesday, November 11th. BMO Capital Markets increased their price objective on Amgen from $335.00 to $372.00 and gave the company an “outperform” rating in a research report on Wednesday, December 3rd. Wells Fargo & Company lifted their target price on Amgen from $300.00 to $325.00 and gave the stock an “equal weight” rating in a report on Wednesday, December 10th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. Finally, Bank of America increased their price target on Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research report on Friday, September 26th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, nine have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $338.55.

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.